Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01300390 · ClinicalTrials.gov registry record
Assessment of Endothelial Function, Apolipoproteins and Adiponectin
A clinical trial, sponsored by Mayo Clinic.
- Completed
- Registry status
- 150
- Enrollment target
NCT01300390: Completed study, sponsored by Mayo Clinic.
NCT01300390 is a clinical trial that has completed, run by Mayo Clinic. The registered enrollment target is 150 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01300390 has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- 150 participants
- Enrollment target
Study Summary
The overall hypothesis is that endothelial function, apolipoprotein levels and adiponectin levels are accurate predictors of underlying cardiovascular disease in patients with end-stage liver disease, in whom standard tools for the diagnosis of and screening for cardiovascular disease are of limited utility.
Primary Outcome
Endothelial function testing will be performed by reactive hyperemia peripheral artery tonometry in consecutive patients ≥21 years old awaiting liver transplantation and repeated at 3 weeks, 4 months and 1 year post transplantation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2011-06 |
| Est. Completion | 2015-10 |
What the finished NCT01300390 record still lists
NCT01300390 is an observational study that tracks outcomes without assigning an intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT01300390 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01300390 about?
NCT01300390 is a clinical study titled "Assessment of Endothelial Function, Apolipoproteins and Adiponectin". The overall hypothesis is that endothelial function, apolipoprotein levels and adiponectin levels are accurate predictors of underlying cardiovascular disease in patients with end-stage liver disease, in whom standard tools for the diagnosis of and screening for cardiovascular disease are of limited...
What is the current status of trial NCT01300390?
This trial is currently completed. The enrollment target is 150 participants. The study started on 2011-06. Estimated completion is 2015-10.
Who is sponsoring clinical trial NCT01300390?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00412594 · 150 participants · Phase 2
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
- NCT01484730 · 150 participants
A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion
- NCT01985919 · 150 participants
Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples
- NCT02016248 · 150 participants · NA
SBRT Boost for Unfavorable Prostate Cancer'
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia